{"altmetric_id":10864878,"counts":{"readers":{"mendeley":8,"citeulike":0,"connotea":0},"total":{"posts_count":21},"twitter":{"unique_users_count":17,"unique_users":["ELShematology","OncologyAdvance","jaimedgeo","edubencla","OncologyForum","AthenaMeetings","erdogan_suat","shiv_smith","Meht_Urology","mlazqui","AntonioGomezC4","urbano_anido","MjosemvI","sogug1","Xemadeyaka14","LuisAlberto3P","afonsera1"],"posts_count":18},"facebook":{"unique_users_count":2,"unique_users":["529920997089266","185704668181421"],"posts_count":3}},"selected_quotes":["Critical Reviews in Oncology\/Hematology- Prostate cancer perspectives after chaarted: Optimizing treatment sequence ht\u2026","Critical Reviews in Oncology\/Hematology- Prostate cancer perspectives after chaarted: Optimizing treatment sequence","What to do after chaarted failure"],"citation":{"abstract":"Prostate cancer is the most frequent cancer amongst men. Until recently, only two therapeutic options, initial androgen-deprivation therapy in patients without castration-resistant prostate cancer, with addition of docetaxel when the disease becomes castration-resistant, were considered as standard. In the last years, new drugs (abiraterone, enzalutamide, Ra-223, Sipuleucel) have been developed for prostate cancer treatment with important advantages in safety and efficacy. Results from the recent Chaarted study, in patients that received docetaxel for the hormone sensitive disease, have contributed to change the initial treatment approach in metastatic prostate cancer, in order to adapt the best sequence for each patient. Those results have been supported by the Stampede trial. Stampede survival data showed not only a benefit in overall survival of adding docetaxel initially, but also a prolonged time to first skeletal related event. Now it is discussed in which setting the available drugs should be administered. This review article summarizes the treatment options for patients treated with docetaxel initially for hormone sensitive prostate cancer after developing progressive disease, and offers an algorithm proposal for treatment.","altmetric_jid":"4f6fa4ea3cf058f610002643","authors":["Sonia Macia","Sergio V\u00e1zquez Est\u00e9vez","Urbano Anido Herranz","Ovidio Fern\u00e1ndez Calvo","Francisco Javier Afonso","Luc\u00eda Santom\u00e9 Couto","Mart\u00edn L\u00e1zaro Quintela","Luis Le\u00f3n Mateos","Luis Miguel Ant\u00f3n Aparicio","Francisco Javier Afonso Afonso","Sonia Maci\u00e1 Escalante"],"doi":"10.1016\/j.critrevonc.2016.08.007","first_seen_on":"2016-08-27T13:00:31+00:00","funders":["niehs"],"issns":["1879-0461","10408428"],"journal":"Critical Reviews in Oncology\/Hematology","last_mentioned_on":1475474637,"links":["https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?redirect=http:\/\/www.croh-online.com\/retrieve\/pii\/S1040842816301846?sf34213033%253D1%2526cc%253Dy&rc=0&code=onch-site","http:\/\/www.sciencedirect.com\/science\/article\/pii\/S1040842816301846?sf34008313%3D1%26cc%3Dy","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?redirect=http:\/\/www.croh-online.com\/retrieve\/pii\/S1040842816301846?sf34008313%253D1%2526cc%253Dy&rc=0&code=onch-site","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?redirect=http:\/\/www.croh-online.com\/retrieve\/pii\/S1040842816301846?cc%253Dy%2526sf34012308%253D1&rc=0&code=onch-site","http:\/\/www.sciencedirect.com\/science\/article\/pii\/S1040842816301846?cc%3Dy%26sf34012308%3D1","http:\/\/www.sciencedirect.com\/science\/article\/pii\/S1040842816301846","http:\/\/www.sciencedirect.com\/science\/article\/pii\/S1040842816301846?via%3Dihub","http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842816301846?via=sd&cc=y&sf34213040=1","http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842816301846?via=sd&cc=y&sf34012314=1","http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842816301846?via=sd&cc=y&sf34008322=1"],"pdf_url":"http:\/\/www.croh-online.com\/article\/S1040842816301846\/pdf","pmid":"27823639","pubdate":"2016-08-21T00:00:00+00:00","publisher":"Elsevier","publisher_subjects":[{"name":"Cardiovascular Medicine And Haematology","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"subjects":["neoplasms","hematology"],"title":"Prostate cancer perspectives after chaarted: Optimizing treatment sequence","type":"article","volume":"107","mendeley_url":"http:\/\/www.mendeley.com\/research\/prostate-cancer-perspectives-after-chaarted-optimizing-treatment-sequence"},"altmetric_score":{"score":10.75,"score_history":{"1y":10.75,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":10.75},"context_for_score":{"all":{"total_number_of_other_articles":7988523,"mean":6.735678058589,"rank":730254,"this_scored_higher_than_pct":90,"this_scored_higher_than":7254099,"rank_type":"exact","sample_size":7988523,"percentile":90},"similar_age_3m":{"total_number_of_other_articles":249331,"mean":12.265864942044,"rank":35544,"this_scored_higher_than_pct":85,"this_scored_higher_than":213547,"rank_type":"exact","sample_size":249331,"percentile":85},"this_journal":{"total_number_of_other_articles":505,"mean":3.7381349206349,"rank":21,"this_scored_higher_than_pct":95,"this_scored_higher_than":484,"rank_type":"exact","sample_size":505,"percentile":95},"similar_age_this_journal_3m":{"total_number_of_other_articles":17,"mean":30.971875,"rank":2,"this_scored_higher_than_pct":88,"this_scored_higher_than":15,"rank_type":"exact","sample_size":17,"percentile":88}}},"demographics":{"poster_types":{"member_of_the_public":10,"researcher":2,"practitioner":5},"users":{"twitter":{"cohorts":{"Members of the public":10,"Practitioners (doctors, other healthcare professionals)":5,"Scientists":2}},"mendeley":{"by_status":{"Student  > Doctoral Student":2,"Researcher":1,"Student  > Ph. D. Student":1,"Other":2,"Student  > Bachelor":1,"Professor":1},"by_discipline":{"Medicine and Dentistry":7,"Economics, Econometrics and Finance":1}}},"geo":{"twitter":{"NL":1,"VE":1,"GB":4,"TR":1,"ES":4}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/ELShematology\/statuses\/769519883524734976","license":"gnip","citation_ids":[10864878],"posted_on":"2016-08-27T13:00:11+00:00","author":{"name":"Elsevier Hematology","url":"http:\/\/www.hematologyadvance.com","image":"https:\/\/pbs.twimg.com\/profile_images\/615567362125889536\/9abt9Dl8_normal.jpg","description":"Tweets about our Hematology books and  journals, related research news for scientists, students, practitioners, industry and everyone else who is interested","id_on_source":"ELShematology","tweeter_id":"1934440580","geo":{"lt":null,"ln":null},"followers":3344},"tweet_id":"769519883524734976"},{"url":"http:\/\/twitter.com\/OncologyAdvance\/statuses\/772418963733094400","license":"gnip","citation_ids":[10864878],"posted_on":"2016-09-04T13:00:06+00:00","author":{"name":"Oncology Advance","url":"http:\/\/oncologyadvance.com","image":"https:\/\/pbs.twimg.com\/profile_images\/888294722263027712\/4fgo7f8y_normal.jpg","id_on_source":"OncologyAdvance","tweeter_id":"41114958","geo":{"lt":52.37403,"ln":4.88969,"country":"NL"},"followers":15546},"tweet_id":"772418963733094400"},{"url":"http:\/\/twitter.com\/jaimedgeo\/statuses\/772422458355879936","license":"gnip","rt":["OncologyAdvance"],"citation_ids":[10864878],"posted_on":"2016-09-04T13:13:59+00:00","author":{"name":"Jaime Diaz","image":"https:\/\/pbs.twimg.com\/profile_images\/696824278638030848\/8Ex8XP_3_normal.jpg","id_on_source":"jaimedgeo","tweeter_id":"696821627594653697","geo":{"lt":null,"ln":null},"followers":208},"tweet_id":"772422458355879936"},{"url":"http:\/\/twitter.com\/edubencla\/statuses\/772461995924844544","license":"gnip","rt":["OncologyAdvance"],"citation_ids":[10864878],"posted_on":"2016-09-04T15:51:06+00:00","author":{"name":"E. Benavides Clavier","image":"https:\/\/pbs.twimg.com\/profile_images\/612264565137653760\/K3MkIljQ_normal.jpg","description":"Onc\u00f3logo Radioterapeuta Medico Nuclear. Radio-Cirug\u00eda Intraoperatoria para C\u00e1ncer de Mama. Unidad Mastolog\u00eda\/Centro Especialidades Anzo\u00e1tegui.","id_on_source":"edubencla","tweeter_id":"387170752","geo":{"lt":9.43889,"ln":-64.47278,"country":"VE"},"followers":304},"tweet_id":"772461995924844544"},{"url":"http:\/\/twitter.com\/OncologyAdvance\/statuses\/772781352362057728","license":"gnip","citation_ids":[10864878],"posted_on":"2016-09-05T13:00:06+00:00","author":{"name":"Oncology Advance","url":"http:\/\/oncologyadvance.com","image":"https:\/\/pbs.twimg.com\/profile_images\/888294722263027712\/4fgo7f8y_normal.jpg","id_on_source":"OncologyAdvance","tweeter_id":"41114958","geo":{"lt":52.37403,"ln":4.88969,"country":"NL"},"followers":15546},"tweet_id":"772781352362057728"},{"url":"http:\/\/twitter.com\/OncologyForum\/statuses\/772880688076972033","license":"gnip","rt":["OncologyAdvance"],"citation_ids":[10864878],"posted_on":"2016-09-05T19:34:50+00:00","author":{"name":"Oncology Forum UK","url":"http:\/\/oncology-forum.co.uk\/","image":"https:\/\/pbs.twimg.com\/profile_images\/900665803720318977\/ZmGs6qGs_normal.jpg","description":"The Oncology Forum is a 1st class medical educational meeting that mixes politics & vital education across pan tumour areas. FREE to Cancer HCPs. Post ASCO.","id_on_source":"OncologyForum","tweeter_id":"2570983608","geo":{"lt":54.75844,"ln":-2.69531,"country":"GB"},"followers":1667},"tweet_id":"772880688076972033"},{"url":"http:\/\/twitter.com\/AthenaMeetings\/statuses\/772919981952626688","license":"gnip","rt":["OncologyAdvance"],"citation_ids":[10864878],"posted_on":"2016-09-05T22:10:58+00:00","author":{"name":"Athena Meetings","url":"http:\/\/www.athenameetings.com","image":"https:\/\/pbs.twimg.com\/profile_images\/1418621540\/Athena_logo_normal.JPG","description":"Specialised #Meetings & #Events #Agency. #VenueFinding #Pharmceutical. Experience, fun and easy team to work with!","id_on_source":"AthenaMeetings","tweeter_id":"326085070","geo":{"lt":54.75844,"ln":-2.69531,"country":"GB"},"followers":992},"tweet_id":"772919981952626688"},{"url":"http:\/\/twitter.com\/erdogan_suat\/statuses\/773742339575676928","license":"gnip","rt":["ELShematology"],"citation_ids":[10864878],"posted_on":"2016-09-08T04:38:43+00:00","author":{"name":"Suat ERDOGAN","url":"http:\/\/www.suaterdogan.com","image":"https:\/\/pbs.twimg.com\/profile_images\/682450099239178240\/bXyEEKcf_normal.jpg","description":"Prof. Dr.\/Trakya University, School of Medicine\/\nPhD at Glasgow University","id_on_source":"erdogan_suat","tweeter_id":"1077327264","geo":{"lt":41.25,"ln":26.66667,"country":"TR"},"followers":260},"tweet_id":"773742339575676928"},{"url":"http:\/\/twitter.com\/shiv_smith\/statuses\/776838643239583744","license":"gnip","rt":["OncologyAdvance"],"citation_ids":[10864878],"posted_on":"2016-09-16T17:42:20+00:00","author":{"name":"#hellomynameis Shiv","image":"https:\/\/pbs.twimg.com\/profile_images\/889133241353080832\/KcFMMZH1_normal.jpg","description":"Proud to be a nurse\u2764 Emergency care background. RCN AO London - Kings Fund. Present: Jnr Uro-Oncology CNS. Views are totally my own. RT not endorsement.","id_on_source":"shiv_smith","tweeter_id":"2740630786","geo":{"lt":52.04832,"ln":-0.02438,"country":"GB"},"followers":1113},"tweet_id":"776838643239583744"},{"url":"http:\/\/twitter.com\/Meht_Urology\/statuses\/776843982211080192","license":"gnip","rt":["OncologyAdvance"],"citation_ids":[10864878],"posted_on":"2016-09-16T18:03:33+00:00","author":{"name":"MehtUrology","url":"http:\/\/prostatecanceruk.org\/get-support\/find-local-support\/the-walnut-club","image":"https:\/\/pbs.twimg.com\/profile_images\/858343013952520196\/QifQKEPL_normal.jpg","description":"A dedicated and passionate team of individuals 01245 513819 Working hours Monday -Friday 9-6pm","id_on_source":"Meht_Urology","tweeter_id":"3910856969","geo":{"lt":51.73575,"ln":0.46958,"country":"GB"},"followers":535},"tweet_id":"776843982211080192"},{"url":"http:\/\/twitter.com\/mlazqui\/statuses\/782145267424497664","license":"gnip","citation_ids":[10864878],"posted_on":"2016-10-01T09:08:57+00:00","author":{"name":"Mart\u00edn L\u00e1zaro","url":"http:\/\/www.novedadesenoncologia.blogspot.com","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000653691864\/11d6fb0c77217bfce2c907aa9b0f2ee5_normal.jpeg","description":"Medical oncologist. Lung and genitourinary cancer.","id_on_source":"mlazqui","tweeter_id":"196132848","geo":{"lt":42.23282,"ln":-8.72264,"country":"ES"},"followers":1669},"tweet_id":"782145267424497664"},{"url":"http:\/\/twitter.com\/AntonioGomezC4\/statuses\/782190982620147712","license":"gnip","rt":["mlazqui"],"citation_ids":[10864878],"posted_on":"2016-10-01T12:10:37+00:00","author":{"name":"Antonio G. C.","image":"https:\/\/pbs.twimg.com\/profile_images\/615770216279072769\/HM4LF2cP_normal.jpg","description":"El ejemplo es el \u00fanico argumento v\u00e1lido en la vida civil (Edmund Burke)","id_on_source":"AntonioGomezC4","tweeter_id":"3350685418","geo":{"lt":42.88052,"ln":-8.54569,"country":"ES"},"followers":218},"tweet_id":"782190982620147712"},{"url":"http:\/\/twitter.com\/urbano_anido\/statuses\/782200251767726080","license":"gnip","rt":["mlazqui"],"citation_ids":[10864878],"posted_on":"2016-10-01T12:47:27+00:00","author":{"name":"Urbano Anido","image":"https:\/\/pbs.twimg.com\/profile_images\/701328985590988800\/dFM9Y8VG_normal.jpg","description":"Father & husband | Scuba-diver | Medical oncologist | Own opinions & thoughts","id_on_source":"urbano_anido","tweeter_id":"2303944103","geo":{"lt":42.88052,"ln":-8.54569,"country":"ES"},"followers":447},"tweet_id":"782200251767726080"},{"url":"http:\/\/twitter.com\/MjosemvI\/statuses\/782202988983181312","license":"gnip","rt":["mlazqui"],"citation_ids":[10864878],"posted_on":"2016-10-01T12:58:19+00:00","author":{"name":"Mjose MendezVidal","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000792500437\/4f327a27b2426c4544fd0324462caf82_normal.jpeg","description":"Medical Oncologist. Clinical researcher. GU tumor Unit. Hospital universitario Reina Sofia Cordoba Spain","id_on_source":"MjosemvI","tweeter_id":"476714556","geo":{"lt":null,"ln":null},"followers":262},"tweet_id":"782202988983181312"},{"url":"http:\/\/twitter.com\/sogug1\/statuses\/782230368367710208","license":"gnip","rt":["mlazqui"],"citation_ids":[10864878],"posted_on":"2016-10-01T14:47:07+00:00","author":{"name":"SOGUG","image":"https:\/\/pbs.twimg.com\/profile_images\/777058730982662144\/hUowGuNg_normal.jpg","description":"Cuenta oficial del Grupo Espa\u00f1ol de Tumores Genitourinarios \/ Spanish Oncology Genitourinary Group's official account","id_on_source":"sogug1","tweeter_id":"1136854537","geo":{"lt":null,"ln":null},"followers":863},"tweet_id":"782230368367710208"},{"url":"http:\/\/twitter.com\/Xemadeyaka14\/statuses\/782231470786109440","license":"gnip","rt":["mlazqui"],"citation_ids":[10864878],"posted_on":"2016-10-01T14:51:30+00:00","author":{"name":"Xema P\u00e9rez","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000756361229\/739d351e4f914138a6380d0c66e2f909_normal.jpeg","id_on_source":"Xemadeyaka14","tweeter_id":"2184430467","geo":{"lt":null,"ln":null},"followers":374},"tweet_id":"782231470786109440"},{"url":"http:\/\/twitter.com\/LuisAlberto3P\/statuses\/782280065228890112","license":"gnip","rt":["mlazqui"],"citation_ids":[10864878],"posted_on":"2016-10-01T18:04:36+00:00","author":{"name":"Luis P\u00e9rez-Romasanta","image":"https:\/\/pbs.twimg.com\/profile_images\/650180382126669824\/YTTCXapR_normal.jpg","description":"Onc\u00f3logo experto en radioterapia. Curioso, cr\u00edtico, tranquilamente inquieto.\nRadiation Oncologist. Curious, esceptic, quietly restless.","id_on_source":"LuisAlberto3P","tweeter_id":"701554564","geo":{"lt":40.96882,"ln":-5.66388,"country":"ES"},"followers":325},"tweet_id":"782280065228890112"},{"url":"http:\/\/twitter.com\/afonsera1\/statuses\/782823482384154625","license":"gnip","citation_ids":[10864878],"posted_on":"2016-10-03T06:03:57+00:00","author":{"name":"Javier Afonso","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000823666974\/e87306e753126fe80aeb1f74fe8a650a_normal.jpeg","description":"Onc\u00f3logo m\u00e9dico con especial inter\u00e9s en, c\u00e1ncer de pulm\u00f3n y genitourinario.\/ Medical oncologist with special interest in lung and genitourinary cancer.","id_on_source":"afonsera1","tweeter_id":"111417805","geo":{"lt":null,"ln":null},"followers":1039},"tweet_id":"782823482384154625"}],"facebook":[{"url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1105562739525086&id=529920997089266","license":"public","citation_ids":[10864878],"posted_on":"2016-08-27T13:00:16+00:00","summary":"Critical Reviews in Oncology \/ Hematology- Prostate cancer perspectives after chaarted: Optimizing treatment sequence http:\/\/bit.ly\/2bWjKkC","author":{"name":"Elsevier Hematology","url":"https:\/\/www.facebook.com\/529920997089266","facebook_wall_name":"Elsevier Hematology","image":"https:\/\/graph.facebook.com\/529920997089266\/picture","id_on_source":"529920997089266"}},{"url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1094664960618716&id=185704668181421","license":"public","citation_ids":[10864878],"posted_on":"2016-09-05T13:00:10+00:00","summary":"Critical Reviews in Oncology \/ Hematology- Prostate cancer perspectives after chaarted: Optimizing treatment sequence http:\/\/bit.ly\/2bQW1Gb","author":{"name":"OncologyAdvance","url":"https:\/\/www.facebook.com\/185704668181421","facebook_wall_name":"OncologyAdvance","image":"https:\/\/graph.facebook.com\/185704668181421\/picture","id_on_source":"185704668181421"}},{"url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1093752727376606&id=185704668181421","license":"public","citation_ids":[10864878],"posted_on":"2016-09-04T13:00:11+00:00","summary":"Critical Reviews in Oncology \/ Hematology- Prostate cancer perspectives after chaarted: Optimizing treatment sequence http:\/\/bit.ly\/2c43m1I","author":{"name":"OncologyAdvance","url":"https:\/\/www.facebook.com\/185704668181421","facebook_wall_name":"OncologyAdvance","image":"https:\/\/graph.facebook.com\/185704668181421\/picture","id_on_source":"185704668181421"}}]}}